Description
AB-CHMINACA
AB-CHMINACA
AB-FUBINACA is an indazole-based synthetic cannabinoid
AB-FUBINACA is an indazole-based synthetic cannabinoid (CB) with 10-fold greater affinity for the central CB1 receptor (Ki = 0.9 nM) than that of JWH 018 .
AB-FUBINACA was first synthesized by Pfizer, Inc. as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA in illegal herbal products.
AB-CHMINACA is structurally related to AB-FUBINACA with a cyclohexyl group substituted for the 4-fluorophenyl group. The physiological and toxicological properties of this compound have not been determined.
This product is intended for research and forensic applications.
Technical Information
| Formal Name | N- |
| CAS Number | 1185887-21-1 |
| Molecular Formula | C20H28N4O2 |
| Formula Weight | 356.5 |
| Purity | ≥98{1c57b62ff62ece913bdfbee9045512232523ebb0b1c45b23168c29acd37c9569} |
| Formulation | A crystalline solid |
| λmax | 210, 303 nm |
| SMILES | O=C(N[C@H](C(N)=O)C(C)C)C1=NN(CC2CCCCC2)C3=C1C=CC=C3 |
| InChI Code | InChI=1S/C20H28N4O2/c1-13(2)17(19(21)25)22-20(26)18-15-10-6-7-11-16(15)24(23-18)12-14-8-4-3-5-9-14/h6-7,10-11,13-14,17H,3-5,8-9,12H2,1-2H3,(H2,21,25)(H,22,26)/t17-/m0/s1 |
| InChI Key | KJNZIEGLNLCWTQ-KRWDZBQOSA-N |
AB-FUBINACA was first synthesized by Pfizer, Inc. as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA in illegal herbal products.
AB-CHMINACA is structurally related to AB-FUBINACA with a cyclohexyl group substituted for the 4-fluorophenyl group. The physiological and toxicological properties of this compound have not been determined.
This product is intended for research and forensic applications.
Technical Information
| Formal Name | N- |
| CAS Number | 1185887-21-1 |
| Molecular Formula | C20H28N4O2 |
| Formula Weight | 356.5 |
| Purity | ≥98{1c57b62ff62ece913bdfbee9045512232523ebb0b1c45b23168c29acd37c9569} |
| Formulation | A crystalline solid |
| λmax | 210, 303 nm |
| SMILES | O=C(N[C@H](C(N)=O)C(C)C)C1=NN(CC2CCCCC2)C3=C1C=CC=C3 |
| InChI Code | InChI=1S/C20H28N4O2/c1-13(2)17(19(21)25)22-20(26)18-15-10-6-7-11-16(15)24(23-18)12-14-8-4-3-5-9-14/h6-7,10-11,13-14,17H,3-5,8-9,12H2,1-2H3,(H2,21,25)(H,22,26)/t17-/m0/s1 |
| InChI Key | KJNZIEGLNLCWTQ-KRWDZBQOSA-N |
AB-FUBINACA was first synthesized by Pfizer, Inc. as a potent CB1 receptor modulator for potential therapeutic use, but recently was identified along with AB-PINACA in illegal herbal products.
AB-CHMINACA is structurally related to AB-FUBINACA with a cyclohexyl group substituted for the 4-fluorophenyl group. The physiological and toxicological properties of this compound have not been determined.
This product is intended for research and forensic applications.
Technical Information
| Formal Name | N- |
| CAS Number | 1185887-21-1 |
| Molecular Formula | C20H28N4O2 |
| Formula Weight | 356.5 |
| Purity | ≥98{1c57b62ff62ece913bdfbee9045512232523ebb0b1c45b23168c29acd37c9569} |
| Formulation | A crystalline solid |
| λmax | 210, 303 nm |
| SMILES | O=C(N[C@H](C(N)=O)C(C)C)C1=NN(CC2CCCCC2)C3=C1C=CC=C3 |
| InChI Code | InChI=1S/C20H28N4O2/c1-13(2)17(19(21)25)22-20(26)18-15-10-6-7-11-16(15)24(23-18)12-14-8-4-3-5-9-14/h6-7,10-11,13-14,17H,3-5,8-9,12H2,1-2H3,(H2,21,25)(H,22,26)/t17-/m0/s1 |
| InChI Key | KJNZIEGLNLCWTQ-KRWDZBQOSA-N |
Reviews
There are no reviews yet.